

Editor's Comments:

Regarding the article entitled "**EFFECT OF CURCUMIN ON BLOOD GLUCOSE LEVEL AND SOME NEUROBEHAVIORAL RESPONSES IN ALLOXAN-INDUCED DIABETIC SWISS ALBINO MICE**" of the manuscript number **Ms_JAMPS_34323**: Kindly look below my decision report, including many of my comments on this manuscript, which must be corrected by the author before any consideration for publication. Thank you.

Decision report

1. There are some alphabetical errors, like those at line-14, where "thatcurcumin" should be corrected to "that curcumin".
2. There are repetitions, like those at lines-69-70, where "A glucometer was used to measure the blood glucose levels using glucose oxidase principle using the digital glucometer" should be corrected to "A digital glucometer was used to measure the blood glucose levels using the glucose oxidase principle."
3. At line-79, the way of administration of glibenclamide and curcumin (e.g. either as aqueous solution or with diet) should be mentioned.
4. At line-88, the sentence was started with a lowercase letter "between", which should be corrected to an uppercase letter to be "Between the sample and test phases".
5. At line-92, the equations used for calculation of the novel object recognition tasks, including the time spent exploring the two objects that had changed in comparison with the time spent exploring the other object, should be mentioned.
6. At line-96, the version of the SPSS-package, version-14 or -16, should be mentioned.
7. At line-99, the number of table should be mentioned to be "Table 1".
8. At line-111, the name of the control group (either diabetic or normal control) and the day (either day 0 or day 21), used for comparison, should be mentioned.
9. At line-116, the punctuation and uppercase letter of the word "With" should be corrected to be "difference after 21 days treatment, with curcumin even showing higher percentage glycemic change".
10. At line-132, the comparison groups, to which the superscripts "a" and "b" indicate, are unclear and should be clarified and mentioned, defining whether these comparison groups are either diabetic or normoglycemic controls, also defining the day (day 0 or day 21).
11. At line-143, 'specie' should be corrected to "species".

12. At line-159, "any significant ($p<0.05$)" should be corrected to "any significant change or difference ($p<0.05$)".
13. At line-169, the uppercase letter in "Showed" should be corrected to a lowercase to be "Figure 1 showed".
14. At line-190, the abbreviation "CI" should be defined to be "cognitive index "CI"".
15. At line-191, "interleukin- (IL-) 1β , and IL-6, have been shown" should be corrected to "interleukin- (IL-) 1β , and IL-6, which have been shown".
16. At line-202, the name of the research ethic committee, which approved this study, should be mentioned.

Author's Feedback:

1. Alphabetical errors were checked and corrected
2. Repetition was removed
3. Way of administration was included at lines 73-74
4. Line 88 corrected
5. Line 92 was revisited and formula provided
6. Version provided
7. Number of table provided
8. Group used for comparison mentioned
9. Line 116 corrected
10. b and a revisited. Comparison made with respect to table 32 are within same groups.
Hence, between pretreatment and post treatment
11. Specie corrected
12. Significant change mentioned
13. Showed corrected
14. CI defined
15. Line 190 revised
16. Committee named